Preview

Вестник дерматологии и венерологии

Расширенный поиск

Кожные формы красной волчанки: патогенез, клиника, диагностика, терапия

https://doi.org/10.25208/0042-4609-2015-0-5-24-33

Полный текст:

Аннотация

На основании обзора литературы в статье рассмотрены новейшие сведения о механизмах развития красной волчанки. Представлена современная классификация специфических и неспецифических поражений кожи при красной волчанке. Подробно описана клиническая картина всех кожных форм красной волчанки. Систематизированы данные о патоморфологических и иммунологических критериях диагностики заболевания, современных методах фармакотерапии красной волчанки.

Об авторах

П. Н. Трофимов
ФГБУ «Северо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова»
Россия


О. В. Антонова
ФГБВОУ ВПО «Военно-медицинская академия им. С.М. Кирова»
Россия


Д. Н. Швырев
ФГКУ «442 Военно-клинический госпиталь Западного военного округа»
Россия


В. Р. Хайрутдинов
ФГБВОУ ВПО «Военно-медицинская академия им. С.М. Кирова»
Россия


И. Э. Белоусова
ФГБВОУ ВПО «Военно-медицинская академия им. С.М. Кирова»
Россия


А. В. Самцов
ФГБВОУ ВПО «Военно-медицинская академия им. С.М. Кирова»
Россия


Список литературы

1. Werth V.P. Cutaneous lupus: insights into pathogenesis and disease classification. Bull. NYU Hosp Jt Dis 2007; 65: 200-204.

2. Gronhagen C.M., Fored C.M., Linder M. et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012 Aug; 167 (2): 296-305.

3. Boeckler P., Cosnes A., Frances C. et al. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009 Sep; 145 (9): 1012-6.

4. Schwartzman-Morris J., Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol 2012: 604892.

5. Durosaro O., Davis M.D., Reed K.B., Rohlinger A.L. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009 Mar; 145 (3): 249-53.

6. Gronhagen C.M., Fored C.M., Granath f., Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 2011, 164 (6): 1335-1341.

7. Jarukitsopa S., Hoganson D.D., Crowson C.S. et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus in a predominantly white population in the United States. Arthritis Care Res (Hoboken) 2014 Nov 4. doi: 10.1002/ acr.22502.

8. Yu C., Chang C., Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun 2013; 41: 34-45. Литература

9. Freutel S., Gaffal E., Zahn S. et al. Enhanced CCR5ÆCR3 T helper cell ratio in patients with active cutaneous lupus erythematosus. Lupus 2011; 20: 1300-4.

10. Yang J., Chu Y., Yang X. et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472-83.

11. Clemens S., Michael B., Josef S.S. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 2010; 35: 269-75.

12. Kuhn A., Wozniacka A., Szepietowski J. et al. Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. J Invest Dermatol 2011; 131: 1622-30.

13. Martin D.A., Elkon K.B. Apoptosis. In: Wallace D.J., editor. Dubois' lupus erythematosus. Philadelphia: Lippincott Willians & Willians 2007; 118-132.

14. Seitz C.S., Brocker E.B., Trautmann A. Linear variant of chronic cutaneous lupus erythematosus: a clue for the pathogenesis of chronic cutaneous lupus erythematosus? Lupus 2008; 17: 1136-1139.

15. Dey-Rao R., Sinha A.A. Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation Genomics 2014 Nov 18, doi:10.1016/j. ygeno.2014.11.004.

16. Rekvig O.P., Van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol 2014; 36: 301-311.

17. Wenzel J., Zahn S., Bieber T., Tuting T. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301: 83-86.

18. Beutner E.H., Blaszczyk M., Jablonska S. et al. Studies on criteria of the European Academy of Dermatology and Venerology for the classification of cutaneous lupus erythematosus. I. Selection of clinical groups and study factors. Int J Dermatol 1991 Jun; 30 (6): 411-7.

19. Kuhn A., Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 2014 Feb-Mar; 48-49: 14-9.

20. Gronhagen C.M., Nyberg F. Cutaneous lupus erythematosus: An update. Indian Dermatol Online J 2014 Jan; 5 (1): 7-13.

21. Скрипкин Ю.К., Бутов Ю.С., Хамаганова И.В. и др. Поражения кожи при болезнях соединительной ткани. клиническая дерматовенерология. Под ред. Ю.к Скрипкина, Ю.С. Бутова. М: ГЭОТАР-медиа 2009; II: 234-277.

22. Федеральные клинические рекомендации по ведению больных дискоидной красной волчанкой. М: РОДВк 2013; 17.

23. Gilliam J.N., Sontheimer R.D. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1982; 4: 471-5.

24. Sontheimer R.D. The lexicon of cutaneous lupus erythematosus--a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6 (2): 84-95.

25. Al-Refu K., Goodfield M. Hair follicle stem cells in the pathogenesis of the scarring process in cutaneous lupus erythematosus. Autoimmun Rev 2009; 8: 474-7.

26. Arai S., Katsuoka K. Clinical entity of lupus erythematosus panniculitis/lupus erythematosus profundus. Autoimmun Rev 2009; 8: 449-52.

27. Kawakami Y., Kunisada M., Nishigori C. Arcshaped plaque on the forehead. Lupus erythematosus profundus. Acta Derm Venereol 2014 Nov; 94 (6): 747-8.

28. Callen J.P. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol 2006 Feb; 47 (1): 13-27.

29. Viguier M., Pinquier L., Cavelier-Balloy B. et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore) 2001 May; 80 (3): 180-8.

30. Kuhn A., Sonntag M., Ruzicka T. et al. Histopathologic findings in lupus erythematosus tumidus: review of 80 patients. J Am Acad Dermatol 2003 Jun; 48 (6): 901-8.

31. Werth V.P. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005; 4 (5): 296-302.

32. Kuhn A., Bein D., Bonsmann G. The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev 2009; 8: 441-8.

33. Nico M.M., Vilela M.A., Rivitti E.A., Lourenco S.V. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol 2008; 18: 376-81.

34. Moura Filho J.P., Peixoto R.L., Martins L.G. et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol 2014 Jan-Feb; 89 (1): 118-25.

35. Obermoser G., Sontheimer R.D., Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010 Aug; 19 (9): 1050-70.

36. Machado APB, Dykyj M.T., Vandresen N., Skare T.L. Mucocutaneous involvement in systemic lupus erythematosus and its association with autoantibodies. An Bras Dermatol 2008; 83: 323-328.

37. Llanos C., Izmirly P.M., Katholi M. et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60: 3091-7.

38. Biazar C., Sigges J., Patsinakidis N. et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013; 12: 444-54.

39. Bonilla-Martinez Z.L., Albrecht J., Troxel A.B. et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008; 144 (2): 173-80.

40. Klein R.S., Morganroth P.A., Werth V.P. Cutaneous lupus and the cutaneous lupus and the cutaneous lupus erythematosus disease area and severity index instrument. Rheum Dis Clin North Am 2010; 36 (1): 33-51.

41. Renner R., Sticherling M. The different faces of cutaneous lupus erythematosus. G Ital Dermatol Venereol 2009; 144: 135-147.

42. Ackermann A.B. Lupus erythematosus. In: Histologic diagnosis of inflammatory skin diseases. Baltimore: Williams & Wilkins 1997: 525-46.

43. Costner M.I., Sontheimer R.D., Provost T.T. Lupus erythematosus. In: Sontheimer R.D., Provost T.T., editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams&Wilkins 2003: 15-64.

44. Мазуров В.И., Беляева И.Б., Долгих C.B. Инновационные методы диагностики системных аутоиммунных заболеваний. Вестник СПбМАПО. 2009; (3): 3-13.

45. Sticherling M., Bonsmann G., Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 2008; 6: 48-59.

46. Kretz C., Norpo M., Abeler-Dorner L. et al. Antiannexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus. Exp Dermatol 2010; 19: 919-30.

47. Kuhn A., Sticherling M., Bonsmann G.J. Clinical manifestations of cutaneous lupus erythematosus. Dtsch Dermatol Ges 2007 Dec; 5 (12): 1124-37.

48. Jessop S., Whitelaw D.A., Delamere F.M. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009:CD002954.

49. Chang A.Y., Piette E.W., Foering KP. et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011 Nov; 147 (11): 1261-7.

50. Ezra N., Jorizzo J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin Exp Dermatol 2012 Jun; 37 (4): 327-34.

51. Jallouli M., Frances C., Piette J.C. et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a casecontrol study. JAMA Dermatol 2013; 149: 935-40.

52. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011 Dec; 65 (6): e195-213.

53. Alsanafi S., Kovarik C., Mermelstein A.L., Werth V.P. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol 2011 Apr; 17 (3): 142-4.

54. Schultz H.Y., Dutz J.P., Furukawa F. et al. From Pathogenesis, Epidemiology, and Genetics to Definitions, Diagnosis, and Treatments of Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J Invest Dermatol 2015 Jan; 135 (1): 7-12.


Для цитирования:


Трофимов П.Н., Антонова О.В., Швырев Д.Н., Хайрутдинов В.Р., Белоусова И.Э., Самцов А.В. Кожные формы красной волчанки: патогенез, клиника, диагностика, терапия. Вестник дерматологии и венерологии. 2015;(5):24-33. https://doi.org/10.25208/0042-4609-2015-0-5-24-33

For citation:


Trofimov P.N., Antonova O.V., Shvyrev D.N., Khairutdinov V.R., Belousova I.E., Samtsov A.V. Cutaneous lupus erythematosus: pathogenesis, clinical pattern, diagnostics, therapy. Vestnik dermatologii i venerologii. 2015;(5):24-33. (In Russ.) https://doi.org/10.25208/0042-4609-2015-0-5-24-33

Просмотров: 260


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0042-4609 (Print)
ISSN 2313-6294 (Online)